Cargando…

DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?

Detalles Bibliográficos
Autor principal:	Shannon, Richard P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609569/ https://www.ncbi.nlm.nih.gov/pubmed/23520281 http://dx.doi.org/10.2337/db12-1794

Ejemplares similares

Neuroprotective properties of DPP‐4i: A therapeutic target for dementia prevention in elderly diabetic patients?
por: Umemura, Toshitaka, et al.
Publicado: (2023)

COVID-19 and diabetes: Can DPP4 inhibition play a role?
por: Iacobellis, Gianluca
Publicado: (2020)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

Open Chromatin State of Dpp4 With Glucocorticoid Treatment—Setting up Shop for Metasteroid Diabetes?
por: Morrow, Nadya M, et al.
Publicado: (2021)

DPP‐4 inhibition and islet function
por: Ahrén, Bo
Publicado: (2011)

DPP4 inhibition prevents AKI
por: Reichetzeder, Christoph, et al.
Publicado: (2017)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease
por: Pariyar, Ramesh, et al.
Publicado: (2022)

DPP-4 Inhibition and the Path to Clinical Proof
por: Ahrén, Bo
Publicado: (2019)

Do statins lower testosterone and does it matter?
por: Sniderman, Allan D, et al.
Publicado: (2013)

Reimbursement Policies for Diabetes Prevention Program (DPP): Implications for Racial and Ethnic Health Disparities
por: Formagini, Taynara, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
por: Darsalia, Vladimer, et al.
Publicado: (2018)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Argon neuroprotection
por: Sanders, Robert D, et al.
Publicado: (2010)

Structural and biochemical mechanisms of NLRP1 inhibition by DPP9
por: Huang, Menghang, et al.
Publicado: (2021)

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
por: Evans, Marc, et al.
Publicado: (2015)

Myasthenia Gravis: Do the Subtypes Matter?
por: Murthy, J. M. K.
Publicado: (2020)

Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis
por: Schulz, Kirsten, et al.
Publicado: (2015)

Are volatile anesthetics neuroprotective or neurotoxic?
por: Zuo, Zhiyi
Publicado: (2012)

Seeking neuroprotection in multiple sclerosis: an ongoing challenge
por: Antel, Jack P., et al.
Publicado: (2023)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Blood Pressure Targets for Older Patients—Do Advanced Age and Frailty Really Not Matter?
por: Giffin, Amanda, et al.
Publicado: (2020)

Is DPP4 inhibition a comrade or adversary in COVID-19 infection
por: Dalan, Rinkoo
Publicado: (2020)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

The Neuroprotective Effects of Thymoquinone: A Review
por: Farkhondeh, Tahereh, et al.
Publicado: (2018)

A Coming of Age for Glaucoma Neuroprotection
por: Johnson, Thomas V.
Publicado: (2023)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Do the charges matter?—balancing the charges of the chromodomain proteins on the nucleosome
por: Hiragami-Hamada, Kyoko, et al.
Publicado: (2019)

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
por: Ahrén, Bo
Publicado: (2008)

DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
por: Hasegawa, Yu, et al.
Publicado: (2017)

DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
por: Scheen, André J.
Publicado: (2021)

DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice
por: Herman, Allison B., et al.
Publicado: (2023)

Neuroprotective and neurorestorative potential of xenon
por: Lavaur, J, et al.
Publicado: (2016)

Closed Gateways — Can Neuroprotectants Shield the Retina in Glaucoma?
por: Velpandian, Thirumurthy
Publicado: (2012)

DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages
por: de Vasconcelos, Nathalia M, et al.
Publicado: (2019)

Inhibition of Podocytes DPP4 Activity Is a Potential Mechanism of Lobeliae Chinensis Herba in Treating Diabetic Kidney Disease
por: Wang, Xinyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8c5dq5i629vf86uk55lor7vhsg